Availability of Observational Data for the Analysis of Second-Line Pharmacological Agents for Type 2 Diabetes Mellitus (T2DM)
| The deadline for submissions for this RFI was on Friday, August 9, 2019. We are no longer accepting submissions. Thank you. |
Following the release of findings from the EMPA-REG OUTCOME trial (empagliflozin; SGLT2 inhibitor) in late 2015 indicating that empagliflozin may have a cardiovascular protective effect in patients with type 2 diabetes mellitus (T2DM) at high-risk for cardiovascular events, PCORI began to explore the potential value of a head-to-head comparison of second-line treatments for T2DM.1 This study would assess the difference in cardiovascular outcomes in a patient population including those at low to moderate risk for cardiovascular events.
Subsequent findings from the LEADER (liraglutide; GLP-1 receptor agonist)2, SUSTAIN-6 (semaglutide; GLP-1 receptor agonist)3, CANVAS (canagliflozin; SGLT2 inhibitor)4, and DECLARE (dapagliflozin; SGLT2 inhibitor)5 trials, all of which found cardiovascular benefit associated with the addition of either an SGLT2 inhibitor or a GLP-1 receptor agonist for at least a subset of outcomes, have underscored the timeliness and potential value of such a study.
The higher costs of these newer agents and their potential impact on cardiovascular disease endpoints make a study comparing them with older, lower-cost treatments (sulfonylureas and DPP-4 inhibitors) of importance to patients and clinicians.
While a large-scale randomized controlled trial on this topic would be desirable, the resources required to conduct such a trial limit its feasibility. PCORI is exploring whether a methodologically robust observational study may be a possible alternative or precursor to a large-scale randomized trial. Accordingly, PCORI seeks information about the availability of existing data sources needed to conduct an observational comparative effectiveness study that emulates a clinical trial on this important question.
For questions and inquiries about this RFI, please email [email protected].
Posted: May 24, 2019; Updated: August 28, 2019
_____________________________
1 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-28.
2 Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-22.
3 Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-44.
4 Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57.
5 Wiviott S, Raz I, Bonaca M, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;280:347-357.
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
